Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States have?
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States has 49 citations in the OpenAlex counts ScholarIQ stores.
When was Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States published?
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States has 2015 year in the ScholarIQ index.
What is the open-access status of Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States?
Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States has bronze oa status in the ScholarIQ index.
What is the DOI of Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States?
The DOI for Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States is on the source record.
What is the PMID of Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States?
The PMID for Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States is on the source record.
What is the OpenAlex record for Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States?
The OpenAlex for Clinical and Economic Burden of Antineutrophil Cytoplasmic Antibody–associated Vasculitis in the United States is on the source record.